Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism?
Primary aldosteronism (PA) is the most common cause of secondary hypertension. The diagnosis of PA is of clinical importance for choosing the appropriate treatment, meaning, surgery for the unilateral disease, and inclusion of aldosterone antagonists in the antihypertensive treatment for the bilateral disease. Current diagnostic approaches showed that the prevalence of PA is much higher than previously estimated. There is still controversy regarding the true prevalence of PA in hypertensive patients. The gold standard for differentiating between unilateral and bilateral disease is the adrenal vein sampling (AVS), a method that is invasive and is performed accurately in only few dedicated centers. Non invasive methods (imaging) for discriminating the two entities are: the CT scan, MRI and iodocholesterol (NP-59) scintigraphy performed under dexamethasone suppression. But the accuracy of imaging compared to AVS is suboptimal and can result in wrong therapeutic decisions. NP-59 scintigraphy is a non-invasive functional imaging technique that reveals the adrenal cortical autonomic function and could have of incremental value over anatomical imaging. In conclusion, in previous years NP-59 scintigraphy was used infrequently, but recently with the advent of hybrid single photon emission tomography (SPET/CT) systems the interest in NP-59 scintigraphy has been renewed. Studies comparing NP-59 SPET/CT imaging with AVS are warranted in order to establish its diagnostic accuracy.